Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-039805
Filing Date
2023-08-08
Accepted
2023-08-08 16:10:28
Documents
73
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvmd-20230630.htm   iXBRL 10-Q 3567674
2 EX-31.1 rvmd-ex31_1.htm EX-31.1 20753
3 EX-31.2 rvmd-ex31_2.htm EX-31.2 20704
4 EX-32.1 rvmd-ex32_1.htm EX-32.1 10628
5 EX-32.2 rvmd-ex32_2.htm EX-32.2 10618
  Complete submission text file 0000950170-23-039805.txt   11767378

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvmd-20230630_pre.xml EX-101.PRE 335475
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvmd-20230630_lab.xml EX-101.LAB 470045
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvmd-20230630_def.xml EX-101.DEF 187681
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvmd-20230630.xsd EX-101.SCH 61011
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvmd-20230630_cal.xml EX-101.CAL 54288
67 EXTRACTED XBRL INSTANCE DOCUMENT rvmd-20230630_htm.xml XML 2427930
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39219 | Film No.: 231151381
SIC: 2836 Biological Products, (No Diagnostic Substances)